JID: YMSY

ARTICLE IN PRESS

Surgery 000 (2018) 1-7

ELSEVIER

Contents lists available at ScienceDirect

Surgery

[m5G;May 21, 2018;20:25]



journal homepage: www.elsevier.com/locate/surg

Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma

Andrea Ruzzenente^a, Fabio Bagante^a, Francesco Ardito^b, Tommaso Campagnaro^a, Iole Scoleri^b, Simone Conci^a, Calogero Iacono^{a,*}, Felice Giuliante^b, Alfredo Guglielmi^a

^a General and Hepatobiliary Surgery, Department of Surgery, University of Verona, School of Medicine, Italy ^b Hepatobiliary Surgery Unit, Department of Surgery, Catholic University of Rome, School of Medicine, Italy

ARTICLE INFO

Article history: Accepted 2 March 2018 Available online xxx

ABSTRACT

Background: The performances of the American Joint Committee on Cancer staging systems of the 7th and 8th edition were compared using a cohort of patients undergoing surgery for perihilar cholangiocarcinoma at 2 tertiary referral Italian hepatobiliary centers.

Methods: The American Joint Committee on Cancer 7th and 8th edition staging systems were used to classify 214 patients who underwent surgery for perihilar cholangiocarcinoma. The performances of the 2 staging systems were compared using the concordance index.

Results: Using the American Joint Committee on Cancer 7th edition staging system, we found that the 5-year overall survival for stages I, II, and IVa was 71%, 34%, and 34%, while no patients in stages IIIa, IIIb, and IVb survived 5 years. In comparison, when the American Joint Committee on Cancer 8th edition staging system was used, the 5-year overall survival was 71% and 35% in stages I and II, resulting in 23%, 19%, and 22% in stages IIIa, IIIb, and IIIc, respectively. Of note, no patients in stages IVa and IVb survived 5 years. The American Joint Committee on Cancer 8th edition staging system had a slightly better discriminatory ability with a concordance index of 0.624 compared with 0.619 for the American Joint Committee on Cancer 7th edition.

Conclusion: The newly released classification American Joint Committee on Cancer 8th edition staging system demonstrated a poor to moderate ability to predict prognosis of patients undergoing liver resection for perihilar cholangiocarcinoma, which was only slightly better than the previous edition. Further refinements are needed to improve the prognostic ability of the American Joint Committee on Cancer staging system for perihilar cholangiocarcinoma.

© 2018 Elsevier Inc. All rights reserved.

Introduction

Perihilar cholangiocarcinoma (PH-CCA) is the second most common primary liver cancer.

Even though resection still represents the only possible curative treatment, the prognosis of patients after surgery remains dismal.^{1,2} The American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) staging system is the most common clinical tool to predict the prognosis of PH-CCA patients undergoing curative intent surgery. Recently, the new TNM AJCC 8th edition introduced several changes to better discriminate the prog-

https://doi.org/10.1016/j.surg.2018.03.012 0039-6060/© 2018 Elsevier Inc. All rights reserved. nosis of PH-CCA patients.³⁻⁶ In particular, while patients with a Bismuth-Corlette Type IV PH-CCA (involving the second-order biliary radicals bilaterally) were in stage T4 according to the AJCC 7th edition, the Bismuth-Corlette classification was removed from the new TNM classification; in the 8th edition, stage T4 is now defined as tumor invading the main portal vein or its branches bilaterally, the common hepatic artery, or the unilateral, second-order biliary radicals with contralateral portal vein or hepatic artery involvement.⁴ Moreover, the 8th edition introduced substantial changes in the nodal staging of patients with PH-CCA. While the location of metastatic lymph nodes (LN) determined the N stage in the 7th edition (N1, regional LN metastasis; N2, periaortic, pericaval, superior mesenteric artery, and/or celiac artery LN metastasis), the 8th edition defined stage N1 as patients with 1-3 metastatic lymph nodes and stage N2 as patients with >3 lymph nodes.⁷ Even though Ebata et al,⁸ investigating the long-term outcomes of

Please cite this article as: A. Ruzzenente et al., Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma., Surgery (2018), https://doi.org/10.1016/j.surg.2018.03.012

^{*} Corresponding author: Department of Surgery, Division of General and Hepatobiliary Surgery, School of Medicine, University of Verona, Piazzale L. Scuro, 1, Verona, 37123, Italy.

E-mail address: calogero.iacono@univr.it (C. Iacono).

2

ARTICLE IN PRESS

A. Ruzzenente et al./Surgery 000 (2018) 1-7

1,352 patients undergoing liver resection for PH-CCA at Japanese HPB centers, reported that the new T4 and N stages were more accurate in predicting patient prognosis, the new AJCC 8th edition staging system for PH-CCA has not yet been tested in patients undergoing surgery in Western centers. For these reasons, the present study sought to evaluate and validate the newly published AJCC 8th edition staging system, using a large series of patients who underwent surgery for PH-CCA at 2 tertiary-referral Western hepatobiliary (HPB) centers.

Materials and Methods

Patient demographic and clinical data

Patients undergoing operative intervention for PH-CCA between 2000 and 2015 at 2 major HPB centers in Italy (University of Verona, School of Medicine, Verona, Italy, and Catholic University of Rome, School of Medicine, Rome, Italy) were identified. Only patients with a histologically confirmed PH-CCA were included in the study, while patients who died within 90 days of the operation were excluded from the analyses. PH-CCA were defined as cholangiocarcinoma involving the hilar bile duct (the duct located topologically between the right side of the umbilical portion of the left portal vein and the left side of the origin of the right posterior portal vein).⁹ The institutional review board of each institution approved the study.

Standard patient demographic and clinicopathologic data were collected, including age, sex, American Society of Anesthesiologists (ASA) classification, and presence of cirrhosis. Serum levels of carcinoembryonic antigen (CEA) and Cancer Antigen 19-9 (CA 19-9) were also collected. We also collected data regarding treatment characteristics, including receipt of neoadjuvant chemotherapy, type of operation, and receipt of adjuvant treatments. The status of the resection margin was classified as microscopically negative (R0), microscopically positive (R1), and macroscopically positive (R2). Tumor-specific characteristics, including tumor size, number of tumors, involvement of the liver parenchyma, histologic grade, number and site (according to the Japanese classification) of lymph nodes achieved, and number of metastatic lymph nodes were collected. Lymph nodes of the hepatoduodenal ligament, the proper hepatic artery, and of the posterior surface of the head of the pancreas were dissected routinely and retrieved; interaortocaval lymph nodes were retrieved when macroscopically abnormal. The operative technique included complete dissection of the hilar structures, as well as all the fatty and lymph nodal tissue surrounding the common hepatic artery, the main portal vein, and the bile duct. Presence of lymphovascular/perineural/biliary invasion and direct invasion of the portal vein and the hepatic artery were also recorded. Data on tumor stage were collected according to both the 7th and the 8th editions of AJCC staging systems. Perioperative complications and mortality were considered within 90 days from the date of operation.

Statistical analysis

Continuous variables were summarized as medians with interquartile ranges (IQR), while categorical variables were reported as whole numbers and percentages. The outcome for survival analyses was overall survival (OS), defined as the time interval between the date of surgery and the date of death. Time was censored at the date of last follow-up for living patients. Estimates of OS were calculated using the Kaplan-Meier method. Cox proportional hazards models were used to evaluate associations between tumor stage and OS. In the survival analysis, the clinicopathologic variables resulting in a statistically significant value (P < .05) in the univariate analysis were tested using a Cox multivariable model to

fabl	e 1	
------	-----	--

Baseline characteristics (n = 214)

Variables n (%) Sex Female 96 (44.8) Male 118 (55.2) Age, median (IQR) 65.7 years (57.7–71.5) Type of resection 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 70 (32.7) Right hepatectomy 19 (8.9) Right trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 210 (98.1) Not performed 210 (98.1) Performed 28 (13.1) Vascular resection 86 (86.9) Performed 28 (13.1) Vascular resection 186 (86.9) Performed 30 (14.0) Caudate lobe resection 184 (85.9) Not performed 65 (30.4) Performed 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 131 (61.2) Type I 10 (4.7) Type I 10 (27.7) Type III 20 (23.7)		
Sex Female 96 (44.8) Male 118 (55.2) Age, median (IQR) 6.5.7 years (57.7–71.5) Type of resection 30 (14.0) Left hepatectomy 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 9 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 4 Not performed 210 (98.1) Performed 4 Portal vein resection 4 Not performed 186 (86.9) Performed 28 (13.1) Vascular resection 10 (98.1) Not performed 65 (30.4) Performed 30 (14.0) Caudate lobe resection 131 (61.2) Rt 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 131 (61.2) Type II 10 (4.7) Type II 10 (4.7) Type II 10 (4.7) Type III 10 (19.1) <td< td=""><td>Variables</td><td>n (%)</td></td<>	Variables	n (%)
Female 96 (44.8) Male 118 (55.2) Age, median (IQR) 65.7 years (57.7-71.5) Type of resection 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 7 (3.3) Performed 210 (98.1) Performed 28 (13.1) Vascular resection 88 (86.9) Performed 28 (13.1) Vascular resection 84 (85.9) Performed 184 (85.9) Performed 30 (14.0) Caudate lobe resection 184 (85.9) Not performed 184 (85.9) Performed 184 (85.9) Performed 184 (85.9) R0 131 (61.2) R1 61 (28.5) R2 10 (4.7) Type I 10 (4.7) Type II 10 (4.7) Type II 10 (4.7) Type II 13 (51.2)	Sex	
Male 118 (55.2) Age, median (IQR) 65.7 years (57.7-71.5) Type of resection 30 (14.0) Left tresection 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 19 (8.9) Right trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 7 (3.3) Performed 210 (98.1) Performed 28 (13.1) Vascular resection 186 (86.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 184 (85.9) Margins 131 (61.2) R1 61 (28.5) R2 22 (20.3) Bismuth-Corlette classification 11 Type II 28 (13.3) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.2) Type IIV 52 (24.6)	Female	96 (44.8)
Age, median (IQR) 65.7 years (57.7–71.5) Type of resection 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 7 (3.3) Hepatic artery resection 4 Not performed 210 (98.1) Performed 4 Portal vein resection 86 (86.9) Not performed 28 (13.1) Vascular resection 84 (85.9) Not performed 184 (85.9) Performed 30 (14.0) Caudate lobe resection 10 (4.0) Caudate lobe resection 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 10 (4.7) Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 10 (4.7) Type III 28 (13.3) Type IV 52 (24.6) NA 3	Male	118 (55.2)
Type of resection 30 (14.0) Left hepatectomy 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection 7 (3.3) Not performed 210 (98.1) Performed 4 Portal vein resection 86 (86.9) Not performed 184 (85.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 149 (69.6) Margins 80 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 17 Type II 10 (4.7) Type II 28 (13.3) Type III 10 (4.7) Type III 28 (13.3) Type III 10 (4.7) Type III 28 (13.3) Type III 28 (13.3) No 17 (7.9) Ye	Age, median (IOR)	65.7 years (57.7-71.5)
Bile duct resection 30 (14.0) Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 19 (8.9) Right trisectionectomy 7 (3.3) Hepatic artery resection Not performed Not performed 210 (98.1) Performed 4 Portal vein resection Not performed Not performed 186 (86.9) Performed 28 (13.1) Vascular resection 184 (85.9) Performed 30 (14.0) Caudate lobe resection 014.0) Not performed 184 (85.9) Performed 184 (85.9) Performed 184 (85.9) Performed 184 (85.9) Ro 131 (61.2) RI 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 17 Type II 28 (13.3) Type III 28 (13.3) Type IIIb 71 (33.7) Type III 22 (24.6) NA 3 Lymph adenectomy 22 (36.5) <tr< td=""><td>Type of resection</td><td>J</td></tr<>	Type of resection	J
Left hepatectomy 70 (32.7) Right hepatectomy 88 (41.1) Left trisectionectomy 7 (3.3) Hepatic artery resection Not performed Not performed 210 (98.1) Performed 4 Portal vein resection Xa (3.1) Not performed 28 (13.1) Vascular resection Xa (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 149 (69.6) Margins R0 131 (61.2) R1 61 (28.5) R2 R2 22 (10.3) Bismuth-Corlette classification Type I 10 (4.7) Type II Type II 28 (13.3) Type II Type II 28 (13.3) Type II Type II 10 (4.7) Type II Type II 10 (4.7) Type II Type II 23 (21.0) No No 17 (7.9) Yes No 17 (7.9) Yes No 17 (7.9) Yes 103 (48.1)	Bile duct resection	30 (14.0)
Right hepatectomy 88 (41.1) Left trisectionectomy 7 (3.3) Hepatic artery resection 7 (3.3) Not performed 210 (98.1) Performed 4 Portal vein resection 86 (86.9) Performed 28 (13.1) Vascular resection 88 (41.1) Not performed 186 (86.9) Performed 28 (13.1) Vascular resection 10 (4.0) Caudate lobe resection 0 (14.0) Caudate lobe resection 49 (69.6) Margins 82 (13.1) R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 17 (32.7) Type II 28 (13.3) Type IIB 70 (32.7) Type IIB 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy 10 No 17 (7.9) Yes 19 (10.2) NA 17 Harvested lymp	Left hepatectomy	70 (32.7)
Left trisectionetomy 19 (8.9) Right trisectionetomy 7 (3.3) Hepatic artery resection 210 (98.1) Performed 4 Portal vein resection 86 (86.9) Performed 28 (13.1) Vascular resection 86 (86.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 184 (85.9) Not performed 65 (30.4) Performed 149 (69.6) Margins 8 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7 Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 10 (4.7) Type III 10 (4.7) Type III 28 (13.2) No 17 (7.9) Yes 197 (92.1) Lymphadenectomy No Negative	Right hepatectomy	88 (411)
Right trisectionectomy 7 (3.3) Hepatic artery resection 210 (98.1) Performed 4 Portal vein resection 186 (86.9) Performed 28 (13.1) Vascular resection 184 (85.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 184 (85.9) Performed 65 (30.4) Performed 149 (69.6) Margins 8 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 17 (7.9) Type I 10 (4.7) Type II 28 (13.3) Type II 28 (13.3) Type II 28 (13.3) Type IIIb 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy No Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR)<	Left trisectionectomy	19 (8 9)
Hepatic artery resection Not performed 210 (98.1) Performed 4 Portal vein resection 186 (86.9) Performed 28 (13.1) Vascular resection 28 (13.1) Not performed 184 (85.9) Performed 30 (14.0) Caudate lobe resection Not performed Not performed 65 (30.4) Performed 149 (69.6) Margins R R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification Type I Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 50 (23.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy V No 17 (7.9) Yes 197 (92.1) Lymph node status 72 (36.5) Metastatic <	Right trisectionectomy	7 (3 3)
Not performed 210 (98.1) Performed 4 Portal vein resection 186 (86.9) Performed 28 (13.1) Vascular resection 184 (85.9) Performed 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 184 (85.9) Performed 65 (30.4) Performed 65 (30.4) Performed 65 (30.4) Performed 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification Type I Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 50 (23.7) Type III 50 (23.7) Type III 50 (23.7) Type III 70 (23.7) Type III 70 (23.7) Type III 70 (23.7) Type IV 52 (24.6) NA 3 Lymphadenectomy <	Henatic artery resection	7 (3.5)
Not performed 4 Portal vein resection 186 (86.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 149 (69.6) Margins 65 (30.4) Performed 65 (30.4) Performed 65 (30.4) Performed 149 (69.6) Margins 7 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7 Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type III 28 (13.3) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) Yes 197 (92.1) Lymph node status 17 <td>Not performed</td> <td>210 (98.1)</td>	Not performed	210 (98.1)
Portal vein resection * Not performed 186 (86.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 48 (85.9) Performed 30 (14.0) Caudate lobe resection 49 (69.6) Margins 80 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 71 (33.7) Type I 10 (4.7) Type II 28 (13.3) Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIIb 71 (7.9) Yes 197 (92.1) Lymphadenectomy No No 17 (7.9) Yes 197 (92.1) Lymph node status 17 Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) <td>Performed</td> <td>1</td>	Performed	1
Not performed 186 (86.9) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 184 (85.9) Performed 30 (14.0) Caudate lobe resection 149 (69.6) Margins 8 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7 Type I 10 (4.7) Type I 28 (13.3) Type II 28 (13.3) Type II 28 (13.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy No No 17 (7.9) Yes 197 (92.1) Lymph node status Negative Negative 125 (63.5) M4 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, me	Portal vein resection	7
Not performed 100 (80.5) Performed 28 (13.1) Vascular resection 30 (14.0) Caudate lobe resection 30 (14.0) Caudate lobe resection 49 (69.6) Margins 149 (69.6) Margins 8 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7ype I Type I 10 (4.7) Type II 28 (13.3) Type II 28 (13.3) Type II 28 (13.3) Type II 28 (13.3) Type III 28 (13.3) Type IV 52 (24.6) NA 3 Lymphadenectomy 7 No 17 (7.9) Yes 197 (92.1) Ly	Not performed	186 (86.0)
Vascular resection 28 (13.1) Not performed 184 (85.9) Performed 30 (14.0) Caudate lobe resection 149 (69.6) Margins 8 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 10 (4.7) Type I 10 (4.7) Type II 28 (13.3) Type III 28 (13.3) Type III 50 (23.7) Type III 50 (23.7) Type III 50 (23.7) Type III 52 (24.6) NA 3 Lymphadenectomy 17 (33.7) Yype IV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) Yes 197 (92.1) Lymph node status 17 (32.5) Metastatic 72 (36.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 103 (Borformed	28(121)
Not performed 184 (85.9) Performed 30 (14.0) Caudate lobe resection 149 (69.6) Margins 65 (30.4) Performed 149 (69.6) Margins 131 (61.2) R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7 Type I 10 (4.7) Type II 28 (13.3) Type III 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy V No 17 (7.9) Yes 197 (92.1) Lymph node status V Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10)	Vaccular resoction	28 (13.1)
Not performed 30 (14.0) Caudate lobe resection	Vascular resection	194 (95 0)
Performed 30 (14.0) Caudate lobe resection 65 (30.4) Not performed 149 (69.6) Margins 131 (61.2) R0 131 (62.5) R2 22 (10.3) Bismuth-Corlette classification Type I Type I 10 (4.7) Type I 28 (13.3) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy No No 17 (7.9) Yes 197 (92.1) Lymph node status Negative Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) No 211 (51.9) Yes 9 (4.2%) <td>Not performed</td> <td>184 (85.9)</td>	Not performed	184 (85.9)
Not performed 65 (30.4) Performed 149 (69.6) Margins	Performed	30 (14.0)
Not performed 65 (30.4) Performed 149 (69.6) Margins 2 R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification 7 Type I 10 (4.7) Type II 28 (13.3) Type II 28 (13.3) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy V No 17 (7.9) Yes 197 (92.1) Lymph node status V Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (1-3) Complication V No 205 (94.8%) Yes 9 (4.2%	Caudate lobe resection	
Performed 149 (69.6) Margins	Not performed	65 (30.4)
Margins I31 (61.2) R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification Type I Type I 10 (4.7) Type II 28 (13.3) Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy V No 17 (7.9) Yes 197 (92.1) Lymph node status V Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication Ves No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) No 205 (94.8%) Yes 9 (4.2%) <td>Performed</td> <td>149 (69.6)</td>	Performed	149 (69.6)
R0 131 (61.2) R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification	Margins	101 (010)
R1 61 (28.5) R2 22 (10.3) Bismuth-Corlette classification	RO	131 (61.2)
R2 22 (10.3) Bismuth-Corlette classification	R1	61 (28.5)
Bismuth-Corlette classification Type I 10 (4.7) Type II 28 (13.3) Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy 70 (92.1) Lymph node status 17 (7.9) Yes 197 (92.1) Lymph node status 72 (36.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 103 (48.1) No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy . No 141 (65.9%) Yes 73 (34.1%)	R2	22 (10.3)
Type I 10 (4.7) Type II 28 (13.3) Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy 77 (7.9) Yes 197 (92.1) Lymph node status 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (1-3) Complication 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Bismuth-Corlette classification	
Type II 28 (13.3) Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IIIb 71 (33.7) Type IIV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) Yes 197 (92.1) Lymph node status 197 (92.1) Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3–10) Metastatic lymph node, median (IQR) 2 (1–3) Complication 103 (48.1) No 211 (51.9) Yes 9 (4.2%) Adjuvant chemotherapy 9 (4.2%) No 141 (65.9%) Yes 73 (34.1%)	Туре І	10 (4.7)
Type IIIa 50 (23.7) Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) Yes 197 (92.1) Lymph node status 197 (92.1) Lymph node status 2 (36.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy No No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Type II	28 (13.3)
Type IIIb 71 (33.7) Type IV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) Yes 197 (92.1) Lymph node status 197 (92.1) Lymph node status 2 (36.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy Wo No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Type IIIa	50 (23.7)
Type IV 52 (24.6) NA 3 Lymphadenectomy 17 (7.9) No 17 (92.1) Lymph node status 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Type IIIb	71 (33.7)
NA 3 Lymphadenectomy No 17 (7.9) Yes 197 (92.1) Lymph node status Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 2 (11 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy No No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Type IV	52 (24.6)
Lymphadenectomy No 17 (7.9) Yes 197 (92.1) Lymph node status 125 (63.5) Metastatic 72 (36.5) M4 17 Harvested lymph node, median (IQR) 5 (3–10) Metastatic lymph node, median (IQR) 2 (1–3) Complication 211 (51.9) Yes 048.1) Neoadjuvant chemotherapy 305 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) No 141 (65.9%) Yes 73 (34.1%)	NA	3
No 17 (7.9) Yes 197 (92.1) Lymph node status 197 (92.1) Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 213 (48.1) Neoadjuvant chemotherapy No No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Lymphadenectomy	
Yes 197 (92.1) Lymph node status	No	17 (7.9)
Lymph node status Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 103 (48.1) No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Yes	197 (92.1)
Negative 125 (63.5) Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3-10) Metastatic lymph node, median (IQR) 2 (1-3) Complication 2 (11 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 0205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Lymph node status	
Metastatic 72 (36.5) NA 17 Harvested lymph node, median (IQR) 5 (3–10) Metastatic lymph node, median (IQR) 2 (1–3) Complication 2 (11 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Negative	125 (63.5)
NA 17 Harvested lymph node, median (IQR) 5 (3–10) Metastatic lymph node, median (IQR) 2 (1–3) Complication 2 (1–3) No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Metastatic	72 (36.5)
Harvested lymph node, median (IQR) 5 (3–10) Metastatic lymph node, median (IQR) 2 (1–3) Complication 2 No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	NA	17
Metastatic lymph node, median (IQR) 2 (1-3) Complication 211 (51.9) No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy No No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Harvested lymph node, median (IQR)	5 (3-10)
Complication No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy No No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Metastatic lymph node, median (IOR)	2 (1-3)
No 211 (51.9) Yes 103 (48.1) Neoadjuvant chemotherapy 0 No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	Complication	
Yes 103 (48.1) Neoadjuvant chemotherapy 0 No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No No 141 (65.9%) Yes 73 (34.1%)	No	211 (51.9)
Neoadjuvant chemotherapy No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy No 141 (65.9%) Yes 73 (34.1%)	Yes	103 (48.1)
No 205 (94.8%) Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	Neoadiuvant chemotherapy	
Yes 9 (4.2%) Adjuvant chemotherapy 141 (65.9%) Yes 73 (34.1%)	No	205 (94.8%)
Adjuvant chemotherapy 3 (42.8) No 141 (65.9%) Yes 73 (34.1%)	Ves	9 (4 2%)
No 141 (65.9%) Yes 73 (34.1%)	Adjuvant chemotherapy	5 (1.2/0)
Yes 73 (34.1%)	No	141 (65.9%)
10 (04.1%)	Yes	73 (34 1%)
		.5 (5 1.175)

NA, not available.

assess their independency. The coefficients from the Cox models were reported as hazard ratio (HR) with corresponding 95% confidence intervals (CIs). To assess the performance of the 7th and the 8th editions of the AJCC staging systems, the concordance index (C-index) was used.¹⁰ Standard errors, CIs, and *P* values for the C-index were computed by assuming asymptotic normality

Results

Clinicopathologic characteristics of the study group

A total of 214 patients underwent operative intervention for PH-CCA and were included in the study (Table 1). The majority were male (n = 118, 55.2%) and the overall median age was 65.7 years (IQR, 57.7–71.5; Table 1). A major hepatectomy was performed on 184 (86.0%) patients: left hepatectomy in 70 (32.7%), right hepatectomy in 88 (41.1%), and a left and right trisectionectomy in 19 (8.9%) and 7 (3.3%), respectively; the remaining

Please cite this article as: A. Ruzzenente et al., Comparison of the 7th and 8th editions of the American Joint Committee on Cancer Staging Systems for perihilar cholangiocarcinoma., Surgery (2018), https://doi.org/10.1016/j.surg.2018.03.012

Download English Version:

https://daneshyari.com/en/article/8836637

Download Persian Version:

https://daneshyari.com/article/8836637

Daneshyari.com